Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4950740 | 0.77 | PYGM (1.00) | PYGM | |
| SCHEMBL10351643 | 0.67 | PYGM (0.57) | PYGM | |
| SCHEMBL4696617 | 0.62 | PYGM (0.62) | PYGM | |
| SCHEMBL30622506 | 0.61 | PYGM (0.45) | PYGM | |
| SCHEMBL7288547 | 0.57 | — | — | |
| SCHEMBL27286767 | 0.55 | PYGM (0.39) | PYGM | |
| SCHEMBL10481036 | 0.55 | — | — | |
| SCHEMBL28250426 | 0.55 | PYGM (0.39) | PYGM | |
| SCHEMBL16749889 | 0.54 | — | — | |
| SCHEMBL350922 | 0.53 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557115-B2 | Compounds, compositions, and methods | CYTOKINETICS, INC. (US) | 2009-07-07 | — | — | US | disclosed |
| EP-1558083-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1537089-A4 | COMPOUNDS COMPOSITIONS AND METHODS | CYTOKINETICS INC (US) | 2008-04-16 | — | — | EP | disclosed |
| US-20080021050-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2008-01-24 | — | — | US | disclosed |
| US-7211580-B2 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED (US) | 2007-05-01 | — | — | US | disclosed |
| US-20060264449-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2006-11-23 | — | — | US | disclosed |
| EP-1558083-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-08-03 | — | — | EP | disclosed |
| EP-1537089-A2 | COMPOUNDS COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20040142949-A1 | Compounds, compositions, and methods | CYTOKINETICS, INC. | 2004-07-22 | — | — | US | disclosed |
| WO-2004034972-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004009036-A2 | COMPOUNDS COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021050-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | PYGM 307/4885 |
| US-20060264449-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | PYGM 307/4885 |
| US-20040142949-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | PYGM 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.